【摘 要】
：
Background FLT3 mutation is found in about 30 ％of acute myeloid leukemia (AML) patients and several FLT3 inhibitors are undergoing investigation,but clinical efficacies were lower than expected.In pre
【机 构】
：
Department of Hematology and Oncology,Nagoya University Graduate School of Medicine,Nagoya,Japan
【出 处】
：
The 35th World Congress of the International Society of Hema
论文部分内容阅读
Background FLT3 mutation is found in about 30 ％of acute myeloid leukemia (AML) patients and several FLT3 inhibitors are undergoing investigation,but clinical efficacies were lower than expected.In pre-clinical studies,inhibitory effects were mainly evaluated using sole mutant FLT3-expressing cells,while clinically most AML cells harboring FLT3 mutation co-express wild-type(Wt) FLT3.
其他文献
Background The number of uCBT is increasing to the level of 1200 cases per year,which is comparable to those of uBMT and rPBSCT in Japan.However there is few data on the comparative outcomes of adult
Objective To investigate the safety and effectiveness of laparoscopic splenectomy (LS) for immune thrombocytopenia patients with platelet count lower than 10×109/L and the long-term prognosis of LS fo
Backgroud Both peripheral blood (PB) and bone marrow (BM) can be used for molecular monitoring by quantitative real-time RT-PCR (Q-PCR) for chronic myeloid leukemia(CML).Aim To determine whether molec
Objective Impaired megakaryocyte maturation and insufficient platelet production participate in the pathogenesis of primary immune thrombocytopenia (ITP).The demethylating agent,decitabine (DAC) has b
Background CLL is one of the most common forms of leukemia among adults.Despite advances in the treatment of CLL,including chemotherapy,chemoimmunotherapy (CIT),and stem cell transplant (SCT),the dise
Background Although chemoimmunotherapy regimens remain the standard in the initial treatment of younger,fit patients with CLL/SLL,relapses are typical.The treatment of older patients,patients with rel
Background Chronic B lymphoproliferative diseases (BLPD),which are mainly compo sed of chronic lymphocytic leukemia (CLL),hairy cell leukemia (HCL),follicular lymphom a (FL),marginal zone lymphoma (MZ
Background A recent GWAS analysis of B-cell chronic lymphocytic leukemia (CLL) identified 12 risk loci,some of which harbor apoptosis-related tumor suppressor genes.Herein we postulate that miR-3151,l
Background The tumor suppressor TP53 is one of the most frequently altered genes in cancer.Several studies have shown TP53 mutations are frequently detected in patients with therapy-related AML or AML
Introduction Donor cell neoplasms are rare complications of treatment regimens that involve stem cell transplantation for hematological malignancies,myelodysplastic processes,or certain genetic or met